|
|
||||||||
Ann Thorac Surg 2001;72:1492-1495
© 2001 The Society of Thoracic Surgeons
a Department of Cardiac Surgery, Cardiologic Hospital, Lille, France
b Department of Anesthesiology, University of Lille, Lille, France
c Department of Echography, Cardiologic Hospital, University of Lille, Lille, France
Accepted for publication June 20, 2001.
* Address reprint requests to Dr Prat, Service de Chirurgie Cardiaque, Hôpital Cardiologique, Centre Hospitalier Regional Universitaire de Lille, Blvd du Pr J. Leclercq, 59037 Lille Cedex, France
e-mail: aprat{at}chru-lille.fr
| Abstract |
|---|
|
|
|---|
Methods. Between June 1994 and June 2000 a pulmonary autograft aortic root replacement was performed in 11 consecutive patients who had urgent or emergent procedures for active endocarditis with extensive involvement of the aortic root (10 native, 1 prosthetic). Patients ranged in age from 26 to 45 years (median, 33 years). Indications for operation were uncontrolled infection (n = 5), hemodynamic deterioration (n = 3), or both (n = 3). Four patients were in the New York Heart Association class III, 6 in class IV, and 1 was operated on while in cardiogenic shock. Four patients (36%) suffered an embolic cerebrovascular accident preoperatively. The endocarditis affected the mitral valve in 2 patients and the tricuspid valve in 1 patient.
Results. There was no early or late death. Recurrent endocarditis was not detected in any of the patients during the follow-up period ranging up to 72 months (median, 40 months).
Conclusions. The autograft may well be the best substitute for aortic root reconstruction in advanced endocarditis.
| Introduction |
|---|
|
|
|---|
| Material and methods |
|---|
|
|
|---|
Preoperative evaluation
Preoperative transesophageal echocardiography was performed in all patients. A grade IV aortic insufficiency was found in all patients. Moreover, paravalvular lesions were also detected in all of the patients. A moderate to severe mitral valve insufficiency was found in 2 patients, and severe tricuspid valve insufficiency in 1 patient. Anatomic details will be disclosed in the following paragraph. The left ventricular ejection fraction was more than 50% in 7 patients, between 30 and 50% in 3 patients, and less than 30% in 1 patient. The median left ventricular end-diastolic diameter was 65 mm, ranging from 60 mm to 75 mm.
Operative findings
Intraoperative findings correlated closely with those of preoperative transesophageal echocardiography, consisting in annular abscesses (n = 5), aorticomitral junction abscesses (n = 4), septal perforation (n = 1), infective vegetations (n = 9), cusps perforations or destructions (n = 3), aortic sinus wall abscesses (n = 2), and aortaright atrium fistula (n = 1). In addition to the aortic valve, the endocarditis affected the anterior leaflet of the mitral valve in 2 patients (prolapse consecutive to ruptured chordae in 1 patient, leaflet perforation in 1 patient). The tricuspid valve leaflets and chordae tendinae were extensively damaged in 1 patient.
Surgical procedures
Operative techniques for the Ross operation have been previously described in detail [1, 2]. In the context of septic surgical field we followed some specific principles: periannular abscesses were thoroughly debrided and necrotic tissue was excised down to healthy tissue; proximal suture line of the pulmonary autograft was performed with evenly distributed interrupted braided sutures at the level of the aortic annulus, crossing the anterior leaflet of the mitral valve and the membranous septum, or at the level of the lower border of the cleansed cavities. In cases of large tissue loss, autologous glutaraldehyde-tanned pericardial patches were used to close the defect and to ensure secure attachment of the autograft and respect the horizontal plane of the proximal suture line. When a discrepancy in excess of 5 mm between aortic and autograft annulus was found, the proximal suture line was reinforced with a strip of autologous glutaraldehyde-tanned pericardium (2 patients); the use of Teflon felt was prohibited. No aortic annulus enlargement procedure was needed in this group of patients.
Total aortic root replacement with a pulmonary autograft was the method of implantation performed in all patients. The right ventricle outflow tract was reconstructed with a cryopreserved pulmonary homograft conduit in 8 patients. Homografts were supplied by the European Homograft Bank of Brussels (Belgium). Pulmonary homograft sizes ranged from 24 mm to 26 mm (median, 25 mm). In 3 patients the right ventricle outflow tract was reconstructed with a 27-mm or 29-mm Freestyle stentless bioprosthesis, because homografts were not available at the time of operation.
Additional significant surgical procedures were performed in 4 patients. A mitral valve repair was performed in 2 patients: transposition of chordae from the posterior to the anterior leaflet in one and repair of the anterior leaflet with an autologous pericardial patch in the other patient. A cryopreserved mitral homograft was used to replace totally the tricuspid valve and a pericardial patch to close a fistula between aorta noncoronary sinus and right atrium in 1 patient. An autologous pericardial patch was required for closure of a ventricular septal defect in another patient. The cross-clamp time ranged from 93 to 166 minutes (median, 127 minutes) and the cardiopulmonary bypass time from 111 to 189 minutes (median, 156 minutes).
Follow-up
Follow-up was complete in 100% of patients. All the patients were examined at our institution between May 2000 and August 2000. The cumulative follow-up period was 458 months with a minimum of 9 months and a maximum of 72 months (median, 40 months). Postoperative Doppler-echocardiography within 2 weeks of operation and prospective serial evaluations at 6 and 12 months and then at yearly intervals were obtained in 100% of patients.
| Results |
|---|
|
|
|---|
Eight of the 11 patients did not receive transfusion or blood products during hospitalization.
There was no neurologic status impairment after operation.
Antibiotic therapy was continued for 3 to 6 weeks after operation. Duration of antibiotic treatment was determined by the nature of the causative organism, the operative findings, and the clinical response.
Late follow-up
There was no late death. Recurrent endocarditis was not detected in any of the patients during the follow-up period.
There were no thromboembolic events, no repeat operation for autograft or homograft failure, or any other valve-related complications. All the patients are now in New York Heart Association class I.
Postoperative echocardiographic evaluation
The first postoperative evaluation of the pulmonary autograft showed either no incompetence or a trace in 10 patients, and a grade 1 incompetence in 2 patients. Homograft evaluation showed a mean gradient of less than 10 mm Hg in every patient.
At the most recent follow-up, no patient had an aortic insufficiency more than grade 1. Similarly, there was a slight, but not significant, increase of the pulmonary mean gradient (3.9 ± 3.2 mm Hg versus 10.5 ± 6.7 mm Hg).
Postoperative echocardiography was unremarkable in the 3 patients who underwent concomitant mitral and tricuspid valve repairs, and revealed the absence of residual mitral regurgitation and a grade 1-4 tricuspid regurgitation.
| Comment |
|---|
|
|
|---|
Numerous operative techniques have been reported to achieve secure aortic root and left ventricular outflow tract reconstruction and a lower rate of subsequent infection. In severe forms of paravalvular destruction the treatment is usually aortic root replacement with either a composite graft [3, 4] or an homograft [5, 6].
dUdekem and colleagues [7] published their results on radical excision of infected tissues and repair of tissue loss with autologous pericardium and prosthetic valve replacement, with an absence of recurrence at 10 years of 79.9%.
In 1992, Haydock and associates [8] highlighted the superiority of aortic homografts over biological or mechanical prostheses for the treatment of acute endocarditis. In 108 patients (79 homografts and 29 prostheses), the absence of recurrence of infection at 1, 5, and 15 years was 98%, 90%, 72%, respectively, for the homografts, and 87%, 85%, 24% for the prostheses. Subsequently, in many institutions, aortic root replacement with an aortic homograft has now become the treatment of choice for extensive aortic endocarditis [5] with an overall incidence of recurrent of endocarditis ranging from 0% to 10%. In our Department cryopreserved homografts have been used in patients with annular abscesses as well [9]. As of June 1994, in patients aged less than 45 years, the treatment of choice for active endocarditis with paravalvular involvement has been pulmonary autograft aortic root replacement. Aortic homografts are still implanted in older patients.
Recently, with the Ross procedure in this difficult issue, impressive results have been published. Oswalt [10] reported no mortality and no recurrent infection in 20 patients for up to 3.5 years and Pettersson and colleagues [11] reported a 5% mortality and no reinfection in 35 patients for up to 56 months. However, in these series, active and healed endocarditis were not clearly individualized. In our series, including only patients with advanced disease, we had no mortality and no recurrent endocarditis with a median follow-up of 3 years.
Despite its outstanding results, the Ross operation remains controversial and is used infrequently in aortic valve endocarditis. In our series of Ross procedures, the only method used for placing the pulmonary autograft in the aortic position was total aortic root replacement [2]. This procedure is particularly well suited for left ventricular outflow tract reconstruction after extensive debridement of infected and necrotic perivalvular tissue in active endocarditis, and necessary in the vast majority of patients with advanced aortic endocarditis [12].
The advantages of the pulmonary autograft have been clearly established: resistance to infection, virtual absence of thromboembolism, long-term durability superior to any other tissue valve, and excellent hemodynamic performance [2, 12, 13].
Nevertheless, criticism of the Ross operation is often made. This technique constitutes a double valve replacement for a single valve disease, requires longer cross-clamp times, and similar results can be achieved with the use of an aortic homograft. We believe that these drawbacks are more than offset by the advantage of implanting a fully viable valve. Furthermore, we did not experience problems in weaning the patients off bypass with current myocardial protection techniques. In young patients the goal of surgical treatment is to achieve good results not only in the short but also in the long term. Aortic root replacement with an aortic homograft carries the risk of difficult reoperation due to homograft aortic wall calcification. Furthermore, in our tissue bank, there is a relative abundance of pulmonary homografts in larger sizes that we use for our patients, and on the contrary a lack of available of aortic homografts.
Traditionally a cryopreserved pulmonary homograft is used as a pulmonary replacement device for the Ross operation. Because of the urgent or emergent condition, and exclusively when no pulmonary or aortic homograft was available in the tissue bank, we used a stentless porcine bioprosthesis (Freestyle, Medtronic Inc, Minneapolis, MN). We are fully aware of the potential risk of prosthetic valve infection in the right ventricle outflow tract, but we think that this risk is probably very low and we never experienced this problem. Konertz and colleagues [14] reported good short-term results (median follow-up, 12 months) in 9 adult patients with the same device.
In patients with mitral or tricuspid valve involvement, all attempts should be made to achieve valve repair. Should a valve replacement become necessary, then a mitral homograft would be the best substitute to obtain freedom from long-term anticoagulation therapy in all patients [15].
Although a limited number of patients were treated in the present study, we are encouraged by the absence of mortality and recurrence of infection. In the light of our results, we would recommend this operation for extensive active aortic root endocarditis in children and young adults. It should nevertheless be emphasized that, due to its relative complexity, the Ross operation should only be undertaken, particularly in emergency cases, if the surgical team is experienced with this procedure in elective cases.
| References |
|---|
|
|
|---|
Related Article
This article has been cited by other articles:
![]() |
C. Schmidtke, G. Dahmen, and H.-H. Sievers Subcoronary Ross Procedure in Patients With Active Endocarditis Ann. Thorac. Surg., January 1, 2007; 83(1): 36 - 39. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Matalanis, M. Durairaj, P. Shah, and B. Buxton Early and Midterm Results with The Ross Procedure: A Study of The First 31 Cases Asian Cardiovasc Thorac Ann, December 1, 2004; 12(4): 336 - 340. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-M. Grinda, P. Brazille, M.-O. Bricourt, J.-L. Mainardi, G. Gonzales-Canali, C. Piketti, and A. Deloche Pulmonary homograft endocarditis after ross procedure Ann. Thorac. Surg., August 1, 2004; 78(2): 687 - 689. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |